Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
Açar sözlər
Mücərrəd
Təsvir
Homologous Recombination (HR) is a DNA repair mechanism that can repair double-strand DNA breaks. It is the only reliable repair mechanism that can repair the consequences of DNA adducts caused by bifunctional alkylating agents (such as cyclophosphamide, thiotepa or carboplatin). Alternative DNA repair mechanisms exist, but these unavoidably induce DNA mutations, deletions and chromosome aberrations, giving give rise to genetic instability. HRD may be a consequence of inactivation of the BRCA-1 or BRCA-2 genes (as in hereditary breast cancer), but it may also be caused by defects in the Fanconi anemia pathway or by amplification of the EMSY gene. HRD is present in breast cancer cells but not in healthy cells of BRCA-1 or BRCA-2 mutation carriers, and also in about half of the sporadic triple-negative breast cancers.
This phase II/III controlled multicenter trial will investigate the ability of individualized chemotherapy to improve the objective response rate of 'triple-negative' breast cancer (estrogen receptor and progesterone receptor-negative, no HER2 amplification) to preoperative (neoadjuvant) chemotherapy. It will answer the question whether intensified alkylating chemotherapy improves the response rate of tumors with a Homologous Recombination Defect (HRD) and it will gather data required for the design of a phase III study documenting the efficacy of response monitoring by contrast-enhanced MRI in TN breast cancer without HRD.
Tarixlər
| Son Doğrulandı: | 03/31/2017 |
| İlk təqdim: | 01/25/2010 |
| Təxmini qeydiyyat təqdim edildi: | 01/25/2010 |
| İlk Göndərmə: | 01/26/2010 |
| Son Yeniləmə Göndərildi: | 04/12/2017 |
| Son Yeniləmə Göndərildi: | 04/16/2017 |
| Həqiqi Təhsilin Başlama Tarixi: | 12/31/2009 |
| Təxmini İlkin Tamamlanma Tarixi: | 11/30/2019 |
| Təxmini İşin Tamamlanma Tarixi: | 11/30/2029 |
Vəziyyət və ya xəstəlik
Müdaxilə / müalicə
Drug: Carboplatin and Paclitaxel
Drug: non-HRD; response; 3x ddAC
Drug: HRD; 1x ddAC, 2x tCTC
Faza
Qol Qrupları
| Qol | Müdaxilə / müalicə |
|---|---|
| Experimental: HRD; 1x ddAC, 2x tCTC HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion. | Drug: HRD; 1x ddAC, 2x tCTC One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion. |
| Active Comparator: HRD; 3x CP HRD tumors; any response to 3x ddAC; 3 courses of CP | |
| Active Comparator: non-HRD;3x CP non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel | |
| Active Comparator: non-HRD; response; 3x ddAC non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC | Drug: non-HRD; response; 3x ddAC Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy. |
| Active Comparator: non-HRD; response; 3x CP non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel |
Uyğunluq Kriteriyaları
| Təhsil üçün uyğun yaşlar | 18 Years Üçün 18 Years |
| Təhsilə Uyğun Cinslər | All |
| Sağlam Könüllüləri qəbul edir | Bəli |
| Kriteriyalar | Inclusion Criteria: - Proven infiltrating breast cancer with either a primary tumor over 2 cm in size (MRI or ultrasound examination) and/or cytologically proven spread to the axillary lymph nodes. - Patients with 'locally advanced breast cancer' are consequently eligible, including those with ipsilateral supraclavicular lymph node metastases. - The tumor must be HER2/neu-negative (either score 0 or 1 at immunohistochemistry or negative at in situ hybridization [CISH or FISH] in case of score 2 or 3 at immunohistochemistry). - The tumor must be Estrogen receptor (ER) -negative (< 10% nuclear staining at IHC) and Progesterone receptor (PR) -negative (< 10% nuclear staining at IHC). However, the rare tumors that are ER-negative and PR-positive will be eligible, if this pattern of hormone receptor expression can be verified in the NKI-AVL reference pathology lab. - Age 18 to 59 years; patients older than 59 years may be included when considered 'biologically 59 years or younger' (as judged by the investigator). - Performance status: WHO 0 or I. - Adequate bone marrow function (W.B.C. count > 3.0 x 109/l, platelets > 100 x 109/l). - Adequate hepatic function (ALAT, ASAT and bilirubin < 2 x upper limit of normal, or minor abnormalities of these tests judged to be of no consequence by the study coordinator). - Adequate renal function (creatinine clearance > 60 ml/min). - Informed consent Exclusion Criteria: - Previous radiation therapy or chemotherapy. - Other malignancy except carcinoma in situ, unless the other malignancy was treated 5 or more years ago with curative intent without the use of chemotherapy or radiation therapy. - Pregnancy or breast feeding. - Evidence of distant metastases. Staging examinations must have included a chest roentgenogram, an ultrasound examination of the liver and an isotope bone scan. Abnormal uptake on the isotope bone scan can only be accepted if bone metastases were excluded by MRI |
Nəticə
İlkin nəticə tədbirləri
1. Primary endpoint (HRD tumors): Average Neoadjuvant Response Index (NRI) after intensified alkylating therapy in comparison to that after 'standard' neoadjuvant chemotherapy. Primary endpoint (non-HRD tumors): Average Neoadjuvant Response Index (NRI) [end of neo adjuvant chemotherapy]
İkincili Nəticə Tədbirləri
1. Recurrence-free survival and overall survival. [every year]
